New drug shows promise for kids with Sleep-Related epilepsy
NCT ID NCT04625101
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 34 times
Summary
This study tested a new medicine called NBI-827104 in 24 children with a rare form of epilepsy that causes constant brain activity during sleep. The goal was to see if the drug could reduce that activity and improve safety. Children took the drug or a placebo once daily for 13 weeks, and researchers measured brain waves during sleep.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Orange, California, 92868, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Neurocrine Clinical Site
Miami, Florida, 33155, United States
-
Neurocrine Clinical Site
Rochester, Minnesota, 55905, United States
-
Neurocrine Clinical Site
Durham, North Carolina, 27710, United States
-
Neurocrine Clinical Site
Cleveland, Ohio, 44195, United States
-
Neurocrine Clinical Site
Philadelphia, Pennsylvania, 19104, United States
-
Neurocrine Clinical Site
Calgary, Alberta, T3B 6A8, Canada
-
Neurocrine Clinical Site
Dianalund, 4293, Denmark
-
Neurocrine Clinical Site
Barcelona, 08950, Spain
-
Neurocrine Clinical Site
Madrid, 28034, Spain
-
Neurocrine Clinical Site
Basel, 4031, Switzerland
-
Neurocrine Clinical Site
Zurich, 8032, Switzerland
-
Neurocrine Clinical Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.